BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 8687048)

  • 1. [Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
    Perrot JL; Lanthier K; Benoit F; Graille MC; Guy C; Bertheas MF; Cambazard F
    Ann Dermatol Venereol; 1995; 122(10):663-6. PubMed ID: 8687048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].
    Pathol Biol (Paris); 1990 Oct; 38(8):876-80. PubMed ID: 2274396
    [No Abstract]   [Full Text] [Related]  

  • 3. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
    Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
    J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fotemustine for the treatment of melanoma.
    Quéreux G; Dréno B
    Expert Opin Pharmacother; 2011 Dec; 12(18):2891-904. PubMed ID: 22077794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combination of fotemustine-dacarbazine and interferon alpha in the treatment of metastatic malignant melanoma].
    Célérier P; Dreno B; Bureau B; Litoux P
    Ann Dermatol Venereol; 1993; 120(6-7):437-40. PubMed ID: 8279787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma.
    Gill S; Shapiro J; Westerman D; Prince HM
    J Clin Oncol; 2007 Oct; 25(28):4493-4. PubMed ID: 17906211
    [No Abstract]   [Full Text] [Related]  

  • 7. Persistent thrombocytopenia during melanoma treatment with fotemustine.
    Turrisi G; Sozzi P; Marinozzi C; Clerico MA
    Melanoma Res; 2006 Dec; 16(6):543-4. PubMed ID: 17119456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fotemustine in the treatment of brain primary tumors and metastases.
    Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
    Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New toxicity of fotemustine: diffuse interstitial lung disease].
    Bertrand M; Wémeau-Stervinou L; Gauthier S; Auffret M; Mortier L
    Ann Dermatol Venereol; 2012 Apr; 139(4):277-81. PubMed ID: 22482481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Contribution of a new nitrosourea compound: fotemustine].
    Boaziz C
    Pathol Biol (Paris); 1992 Dec; 40(9 Pt 2):964-8. PubMed ID: 1338920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective combined immunochemotherapy with dinitrochlorobenzene and fotemustine in skin and brain metastases of melanoma.
    Göring HD; Zierner A; Kröning Y; Trebing D; Kämpgen E; Bröcker EB
    Melanoma Res; 1998 Aug; 8(4):379. PubMed ID: 9764815
    [No Abstract]   [Full Text] [Related]  

  • 12. Neurological toxicity during metastatic melanoma treatment with fotemustine.
    Khalil Z; Pageot N; Carlander B; Guillot B
    Melanoma Res; 2005 Dec; 15(6):563-4. PubMed ID: 16314745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fotemustine with or without dacarbazine for brain metastases of malignant melanoma.
    Merimsky O; Inbar M; Reider-Groswasser I; Chaitchik S
    Eur J Cancer; 1991; 27(8):1066. PubMed ID: 1832900
    [No Abstract]   [Full Text] [Related]  

  • 14. Isolated limb perfusion with fotemustine after chemosensitization with dacarbazine in melanoma.
    Pontes L; Lopes M; Ribeiro M; Santos JG; Azevedo MC
    Melanoma Res; 1997 Oct; 7(5):417-9. PubMed ID: 9429225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence.
    Bonenkamp JJ; Thompson JF; de Wilt JH; Doubrovsky A; de Faria Lima R; Kam PC
    Eur J Surg Oncol; 2004 Dec; 30(10):1107-12. PubMed ID: 15522559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fotemustine: an overview of its clinical activity in disseminated malignant melanoma.
    Khayat D; Avril MF; Gerard B; Bertrand P; Bizzari JP; Cour V
    Melanoma Res; 1992 Sep; 2(3):147-51. PubMed ID: 1450667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
    Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
    Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fotemustine: muphoran].
    Avril MF
    Ann Dermatol Venereol; 2007 Dec; 134(12):997-1000. PubMed ID: 18166925
    [No Abstract]   [Full Text] [Related]  

  • 19. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine.
    Schallreuter KU; Wenzel E; Brassow FW; Berger J; Breitbart EW; Teichmann W
    Cancer Chemother Pharmacol; 1991; 29(1):85-7. PubMed ID: 1742855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Brain metastases of malignant melanomas].
    Boaziz C; Breau JL; Morere JF; Israël L
    Bull Cancer; 1991; 78(4):347-53. PubMed ID: 1859902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.